Vascular endothelial growth factor receptor (VEGFR), Platelet-derived growth factor receptor (PDGFR), and Fibroblast growth factor receptor (FGFR) (VEGFR, PDGFR, FGFR)

These three receptor families—vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor—are key members of the **receptor tyrosine kinase** superfamily. They are activated by binding their cognate ligands (VEGF, PDGF, or FGF), which drives receptor dimerization, intracellular kinase activation, and downstream signaling cascades involved in **angiogenesis**, **cell proliferation**, differentiation, survival, and migration. Aberrant activation or overexpression is implicated in cancer, particularly through the promotion of tumor angiogenesis. Pharmacological inhibition via **small molecule TKIs** or monoclonal antibodies has proven therapeutic efficacy, but cross-family interactions and compensatory mechanisms pose challenges, such as resistance and limited effectiveness in anti-angiogenic therapy[1][2][3][5][7]. For structured data: each receptor (VEGFR, PDGFR, FGFR) is best treated as a separate entity when possible; grouping is primarily justified when discussing multi-targeted therapeutics or convergent signaling.

Other names

Vascular endothelial growth factor receptorPlatelet-derived growth factor receptorFibroblast growth factor receptorVEGFR1VEGFR2VEGFR3PDGFR-αPDGFR-βFGFR1FGFR2FGFR3FGFR4

Small molecule tyrosine kinase inhibitors (TKIs): Block intracellular kinase domain, inhibit signal transduction and cellular growth, suppress angiogenesis. Monoclonal antibodies: Block ligand-receptor interaction (e.g., Bevacizumab against VEGF). Decoy or dominant-negative mechanisms (VEGFR1 acts as decoy).